Pelthos Therapeutics Inc. — Form 8-K

Pelthos Therapeutics Inc. adopted a new 2026 Equity Incentive Plan effective upon shareholder approval, replacing the 2023 plan. The plan authorizes 500,000 new shares plus carryover shares from the prior plan, with an evergreen feature adding 5% of outstanding shares annually (both common and Series A preferred on as-converted basis). Plan permits grants of stock options, SARs, restricted stock, RSUs, and performance shares to employees, directors, and consultants, with standard terms including fair market value exercise prices and various vesting provisions.